Caris Life Sciences (NASDAQ:CAI) Director Purchases 31,050 Shares

Caris Life Sciences, Inc. (NASDAQ:CAI) Director Jeff Vacirca acquired 31,050 shares of the stock in a transaction on Monday, May 11th. The shares were bought at an average price of $16.15 per share, for a total transaction of $501,457.50. Following the purchase, the director owned 49,671 shares in the company, valued at approximately $802,186.65. This trade represents a 166.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Caris Life Sciences Price Performance

Shares of NASDAQ CAI opened at $15.94 on Tuesday. The firm has a fifty day moving average of $19.04. The firm has a market cap of $4.51 billion and a PE ratio of -2.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35. Caris Life Sciences, Inc. has a fifty-two week low of $15.70 and a fifty-two week high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. Caris Life Sciences had a return on equity of 102.71% and a net margin of 3.75%.The company had revenue of $292.89 million for the quarter, compared to analysts’ expectations of $281.00 million. During the same quarter last year, the business earned ($1.73) earnings per share. Caris Life Sciences’s revenue was up 125.4% on a year-over-year basis. On average, equities analysts expect that Caris Life Sciences, Inc. will post 0.12 EPS for the current year.

Institutional Investors Weigh In On Caris Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in CAI. PointState Capital LP lifted its stake in Caris Life Sciences by 73.0% in the 4th quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after purchasing an additional 2,834,986 shares during the last quarter. UBS Group AG grew its stake in shares of Caris Life Sciences by 825.9% during the fourth quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock worth $58,924,000 after buying an additional 1,948,107 shares during the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Caris Life Sciences by 23,902.9% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,660,280 shares of the company’s stock worth $44,794,000 after buying an additional 1,653,363 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Caris Life Sciences by 185.0% in the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock valued at $65,974,000 after acquiring an additional 1,587,176 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its stake in shares of Caris Life Sciences by 14.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock valued at $248,377,000 after acquiring an additional 1,180,200 shares during the last quarter.

Analyst Ratings Changes

Several research firms recently issued reports on CAI. Robert W. Baird set a $22.00 price target on shares of Caris Life Sciences in a research report on Friday. Wall Street Zen cut shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Canaccord Genuity Group cut their target price on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a research note on Friday, March 13th. New Street Research initiated coverage on Caris Life Sciences in a report on Friday. They issued a “market perform” rating on the stock. Finally, Jefferies Financial Group initiated coverage on Caris Life Sciences in a research note on Monday, April 13th. They issued a “buy” rating and a $28.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.56.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.